Clinical trials
No Disease or Condition is Being Studied clinical trials
Below are recruiting no disease or condition is being studied clinical trials, each written for real people, not researchers. We’re tracking 18,433 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06769113RecruitingPhase 2
Study of HLX43 for advanced esophageal cancer
This trial tests a new drug, HLX43, for people with advanced esophageal squamous cell carcinoma that has stopped responding to or cannot tolerate standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT06553365RecruitingPhase 2
Study of FCN-159 for NF2 nerve sheath tumors
This trial tests an oral drug called FCN-159 for people with NF2-related nerve sheath tumors that cannot be fully removed by surgery or have come back after surgery. It aims to see if the drug can shrink or slow the growth of these tumors.
Beijing, Beijing MunicipalityAges 16 years+ - NCT06771336Recruiting
Study of standard care for jawbone reconstruction after cancer
This trial studies current standard care for people who need jawbone reconstruction after cancer surgery. It aims to document the costs and outcomes of using a piece of bone from another part of the body (a free bone flap) to rebuild the face.
AmiensAges 18 years+ - NCT06763783Enrolling by invitationPhase 4
Shingles vaccine study for people with rheumatic diseases
This study offers the Shingrix shingles vaccine for free to adults with inflammatory rheumatic diseases. It compares how well the vaccine works in people taking immune-suppressing drugs versus those not taking them.
LundAges 18 years+ - NCT06764238RecruitingPhase 2/Phase 3
Treatment study for children with new B-cell ALL (intermediate/high risk)
This trial tests a treatment plan for children and teens newly diagnosed with B-cell acute lymphoblastic leukemia (ALL) that is intermediate or high risk. The goal is to find the best way to treat the cancer and improve outcomes.
Hefei, AnhuiAges 1 month–18 years - NCT06762964RecruitingPhase 2
Dapagliflozin for Failing Fontan Circulation
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT06761521Enrolling by invitation
Monitoring implant health with aMMP-8 test
This study uses a special test to check for inflammation around dental implants. It may help catch problems early and is for people who already have implants.
Helsinki, UusimaaAges Any age - NCT06761417RecruitingPhase 2
Liposomal mitoxantrone for children and young adults with relapsed solid tumors
This trial tests a new form of chemotherapy (liposomal mitoxantrone) for children, adolescents, and young adults whose solid tumors have come back or not responded to treatment. The goal is to see if this combination regimen can help shrink tumors.
BeijingAges 6–24 - NCT06771687Recruiting
High-intensity interval training for heart conduit patients
This study tests whether high-intensity interval training (short bursts of intense exercise) can improve heart function and fitness in people who have a surgical tube (conduit) connecting their right ventricle to their pulmonary artery. It aims to find a safe and effective exercise program for those with this type of congenital heart condition.
Nijmegen, GelderlandAges 12–45 - NCT06770998Recruiting
EEG brain training for PTSD
This study tests a new kind of treatment for PTSD that uses a special brain training system called neurofeedback. You will learn to change your own brain activity in sessions that use EEG sensors on your head, and the goal is to reduce your PTSD symptoms without medication or talk therapy.
Birmingham, AlabamaAges 18–65 - NCT06768216Recruiting
Mediterranean vs. low-fat diet for fatty liver in overweight kids
This trial compares two diets—a Mediterranean-style diet and a low-fat diet—to see which better reduces liver fat in overweight children and teens with fatty liver disease (MASLD). It aims to find a safe, effective eating plan for young people.
New Delhi, National Capital Territory of DelhiAges 8–18 - NCT06765733RecruitingEarly Phase 1
Testing Aleeto for multiple system atrophy (MSA)
This trial tests a new treatment called Aleeto for people with a specific type of multiple system atrophy (MSA-P) who haven't responded well to standard Parkinson's medications. The goal is to see if Aleeto is safe and might help improve symptoms.
Beijing, Beijing MunicipalityAges 30–75 - NCT06763341RecruitingPhase 1
Study of AOH1996 for relapsed or refractory acute myeloid leukemia
This trial tests an experimental drug called AOH1996 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if the drug is safe and helps control the leukemia.
Duarte, CaliforniaAges 18 years+ - NCT06762431RecruitingPhase 1/Phase 2
CAR T-cell therapy plus lenalidomide for CLL
This trial tests a combination of two treatments—CAR T-cells (your own immune cells reprogrammed to attack cancer) and lenalidomide (a pill that boosts the immune system)—for people with chronic lymphocytic leukemia (CLL) that has not responded to or returned after at least one prior treatment. It aims to see if this combination is safe and works better than either alone.
Vitebsk, Select A StateAges 18 years+ - NCT06765317RecruitingPhase 2
Glofitamab therapy for older adults with diffuse large B-cell lymphoma
This trial tests a new combination therapy using glofitamab for people aged 65 or older with diffuse large B-cell lymphoma who have not received prior treatment. The goal is to see if this approach is safe and effective for patients who are considered too frail for standard therapies.
Basking Ridge, New JerseyAges 65–80 - NCT06761560RecruitingPhase 2/Phase 3
Hydroxyurea dosing for children with sickle cell anemia
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Montreal, QuebecAges 6 months–18 years - NCT05625529Recruiting
Study blood test to detect pancreatic cancer early
This trial studies how well a new blood-based test may help find pancreatic cancer earlier. You may join if you’re an adult who fits a specific risk group and can safely provide a blood sample.
San Diego, CaliforniaAges 18 years+ - NCT05930145Recruiting
Two clot-retrievers versus one for acute stroke treatment
This trial compares using two clot-retrievers at the same time versus using just one to remove the clot in an acute ischemic stroke. It may help find a more effective approach to restore blood flow and improve recovery.
EssenAges 18 years+ - NCT06220838RecruitingPhase 1
Study of SC-101 for advanced solid tumors
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
Beijing, Beijing MunicipalityAges 18–80 - NCT06248723Recruiting
Preventing memory decline in older adults with lifestyle changes
This study tests a personalized program of lifestyle changes (diet, exercise, brain training, etc.) to see if it can prevent memory loss and keep older adults independent. You may qualify if you are 60+, have mild frailty, and have certain risk factors for dementia.
MonzaAges 60 years+ - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755060Recruiting
AI-assisted eye care study
This trial tests how artificial intelligence can help doctors make better decisions about eye diseases. It may be a good fit if you have an eye condition and can share your medical records and images.
Zhuhai, GuangdongAges Any age - NCT06753227Enrolling by invitation
Comparing ways to measure valve pressure after TAVI
This trial looks at how well a new method (using echo) compares to the standard invasive method for measuring pressure across the new valve after TAVI. It may help doctors monitor your valve function with less risk.
Munich, BavariaAges 18 years+ - NCT06759636RecruitingPhase 3
Comparing two drugs for low platelets from cancer treatment
This trial tests if a new drug called Romiplostim N01 works better than the standard drug Interleukin-11 for raising low platelet counts caused by cancer treatments like chemotherapy or radiation. If you have low platelets from your cancer therapy, you may be able to join.
Nanjing, JiangsuAges 18–75
Hear when a new No Disease or Condition is Being Studied trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for no disease or condition is being studied?
- Yes. Clin2 currently lists 18,433 recruiting no disease or condition is being studied studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a no disease or condition is being studied trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a no disease or condition is being studied trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.